峰值吸气流速作为慢阻肺预测性治疗生物标志物
本文综述了峰值吸气流速(PIF)作为慢阻肺预测性治疗生物标志物的依据。PIF是在模拟干粉吸入器阻力下吸入时产生的最大气流,具有生物学合理性、良好的重复性和可靠性,可推广使用。当前证据支持PIF用于优化门诊慢阻肺患者及因急性加重住院患者出院前的治疗。
要点
- PIF是在模拟干粉吸入器阻力下测得的吸气最大气流,为生理学指标。
- PIF具有生物学合理性、良好的重复性与可靠性,可推广使用。
- 当前证据支持PIF作为预测性治疗生物标志物,用于优化慢阻肺治疗。
核心结论
- 当前证据支持峰值吸气流速作为预测性治疗生物标志物,用于优化门诊慢阻肺患者及因急性加重住院患者出院前的治疗。
研究设计与样本
- 本文为综述,总结慢阻肺中临床、生理及血液生物标志物,并重点讨论峰值吸气流速作为预测性治疗生物标志物的证据。
主要发现
- 干粉吸入器具有内部阻力、呼吸驱动且流速依赖,需要足够吸气流速以解聚药物颗粒并吸入下呼吸道。
- 峰值吸气流速定义为在模拟干粉吸入器阻力下吸入时产生的最大气流。
- 峰值吸气流速具有生物学合理性、良好的重复性与可靠性,并可推广使用。
临床怎么用
- 可利用峰值吸气流速识别可能或不太可能从干粉药物获益的慢阻肺患者,以优化治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biomarkers in COPD may be clinical (prior exacerbation history), physiologic (FEV1), or blood based (eosinophil count or fibrinogen level). Recent interest in using biomarkers to predict response to therapy in clinical practice has emerged. The benefits of inhaled therapy depend on the correct use of the inhaler, including an appropriate inspiratory flow. Of the available delivery systems, dry powder inhalers are unique because they have an internal resistance, are breath actuated, and are flow dependent. Ideally, the user inhales "forcefully" to generate turbulent energy (determined by an individual's inspiratory flow and the resistance of the device) within the device that disaggregates the powder so that the individual inhales the medication particles into the lower respiratory tract. Because of specific features of dry powder inhalers and the required optimal inspiratory flow, an unmet need exists to identify individuals who are likely or unlikely to benefit from dry powder medications. Peak inspiratory flow, defined as the maximum airflow generated during inhalation against the simulated resistance of a dry powder inhaler, is a physiologic measure that has biological plausibility, has good test characteristics (repeatability and reliability), and is generalizable. Current evidence supports peak inspiratory flow as a predictive therapeutic biomarker to optimize therapy in both outpatients with COPD as well as those hospitalized for an exacerbation before discharge. This approach is consistent with the precepts of precision medicine, which considers differences in a person's biological features, exposure, and lifestyle to prevent and treat disease.
引用
- Mahler DA, Halpin DMG. Peak Inspiratory Flow as a Predictive Therapeutic Biomarker in COPD. Chest. 2021. PMID: 33812852. doi:10.1016/j.chest.2021.03.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。